About Todd Axelrod's nominees
The nominees proposed by Mr.
are the following:
, 66, from Montréal,
, is a senior partner of BCF since 1977 and has completed his studies at the Faculty of Law of Université de Montréal and
Harvard Business School
. His current practice is mainly focused on mergers and acquisitions and on public and private financing. He has been a member of board of directors of corporations and non-profit charitable organizations. He has been a director and president of Club St-Denis de Montréal and of Fondation de l'Hôpital
de Montréal. He is now a director and member of the Executive Committee of Fondation du
hospitalier universitaire de Montréal (CHUM).
, 64, from
Beaconsfield, Quebec, Canada
, is a certified accountant. He has been Vice-President, Finances and Administration of Groupe BMR inc. and of Produits de Piscines Vogue inc. He has performed many mandates in recovery, reorganization, financing and diagnostic of companies in many sectors, generally for institutional investors. His experience with publicly traded companies was acquired while he was acting as interim CFO of Ranaz Corporation, a TSX venture company. He currently is a consultant in finance and reorganization. Mr. Guay also disclosed having acted as chief financial officer of Accessoires de piscine Compétition Inc. from
. This company declared bankruptcy in
, he has acted as chief financial officer of Mechtronix Systems Inc. Mechtronix and affiliated companies declared bankruptcy between June and
Mr. Hans Mäder, 66, from
Valleyfield, Quebec, Canada
, had been president and chief executive officer of Ambrilia Biopharma from
. He has acted as chairman of the board, president and chief executive officer of Procyon Biopharma from 1999 until
. He was responsible for the listing of Procyon's shares on the
Stock Exchange and has negotiated license agreements with pharmaceutical partners. He has been president and chief executive officer for Novartis Pharmaceuticals Inc.
and has held various functions at Sandoz Canada Inc. and Sandoz Pharmaceuticals inc. in
the United States
. He currently acts as consultant for North American biotech and pharma companies.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. Previstage
GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA
PCA3 test is commercialized in
under CE mark and is approved for commercialization in
the United States
. For more information, please visit
This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. Forward-looking statements can be identified by the use of the conditional or forward-looking terminology such as "anticipates", "assumes", "believes", "estimates", "expects", "intend", "may", "plans", "projects", "should", "will", or the negative thereof or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. All such forward-looking statements are made pursuant to the "safe-harbour" provisions of applicable Canadian securities laws. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Corporation's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Corporation's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes and that they should not place undue reliance on these forward‐looking statements. For instance, the forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues, including those related to PROGENSA® PCA3, are based on management expectations and such outcome may vary materially depending on global political and
dependence on collaboration partners, uncertainty of healthcare reimbursement, and marketing and distribution challenges. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.
SOURCE DiagnoCure inc.